Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB [Seeking Alpha]
Abeona Therapeutics (ABEO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point [Seeking Alpha]
Abeona Therapeutics (ABEO) was given a new $17.00 price target by Stifel Nicolaus.
Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: Strong Demand for Zivasskin ... [Yahoo! Finance]